Pure and Applied Chemistry, 2013, Volume 85, No. 2, pp. 343-354, References

Pure Appl. Chem., 2013, Vol. 85, No. 2, pp. 343-354

http://dx.doi.org/10.1351/PAC-CON-12-07-08

Published online 2012-12-07

Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-Pt^II complexes containing long alkane linkers

Jitka Prachařová¹, Olga Nováková², Jana Kašpárková¹, Dan Gibson³ and Viktor Brabec²*

¹ Department of Biophysics, Faculty of Science, Palacky University, 17. listopadu 12, CZ-77146 Olomouc, Czech Republic
² Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, 61265 Brno, Czech Republic
³ Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel

References

1. J. B. Mangrum, N. P. Farrell. Chem. Commun. 46, 6640 (2010). (http://dx.doi.org/10.1039/c0cc01254h)
2. S. Rubino, P. Portanova, A. Albanese, G. Calvaruso, S. Orecchio, G. Fontana, G. C. Stocco. J. Inorg. Biochem. 101, 1473 (2007). (http://dx.doi.org/10.1016/j.jinorgbio.2007.06.024)
3. V. Brabec. Prog. Nucleic Acid Res. Mol. Biol. 71, 1 (2002). (http://dx.doi.org/10.1016/S0079-6603(02)71040-4)
4. D. Wang, S. J. Lippard. Nat. Rev. Drug Discov. 4, 307 (2005). (http://dx.doi.org/10.1038/nrd1691)
5. L. Kelland. Nat. Rev. Cancer 7, 573 (2007). (http://dx.doi.org/10.1038/nrc2167)
6. O. Vrana, V. Brabec, V. Kleinwächter. Anti-Cancer Drug Des. 1, 95 (1986).
7. N. Farrell, L. R. Kelland, J. D. Roberts, M. Van Beusichem. Cancer Res. 52, 5065 (1992).
8. J. W. Williams, Y. Qu, G. H. Bulluss, E. Alvorado, N. P. Farrell. Inorg. Chem. 46, 5820 (2007). (http://dx.doi.org/10.1021/ic700410y)
9. R. Olivova, J. Kasparkova, O. Vrana, M. Vojtiskova, T. Suchankova, O. Novakova, W. He, Z. Guo, V. Brabec. Mol. Pharmaceutics 8, 2368 (2011). (http://dx.doi.org/10.1021/mp200298g)
10. N. Farrell, T. G. Appleton, Y. Qu, J. D. Roberts, A. P. S. Fontes, K. A. Skov, P. Wu, Y. Zou. Biochemistry 34, 15480 (1995). (http://dx.doi.org/10.1021/bi00047a013)
11. N. Farrell, Y. Qu, L. Feng, B. Van Houten. Biochemistry 29, 9522 (1990). (http://dx.doi.org/10.1021/bi00493a005)
12. J. D. Hoeschele, A. J. Kraker, Y. Qu, B. Van Houten, N. Farrell. In Molecular Basis of Specificity in Nucleic Acid-Drug Interactions, B. Pullman, J. Jortner (Eds.), pp. 301–321, Kluwer Academic, Dordrecht (1990).
13. N. Farrell. Cancer Invest. 11, 578 (1993). (http://dx.doi.org/10.3109/07357909309011676)
14. N. Farrell, Y. Qu, U. Bierbach, M. Valsecchi, E. Menta. In Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, B. Lippert (Ed.), pp. 479–496, Wiley-VCH, Weinheim (1999).
15. J. Kasparkova, K. J. Mellish, Y. Qu, V. Brabec, N. Farrell. Biochemistry 35, 16705 (1996). (http://dx.doi.org/10.1021/bi961160j)
16. K. J. Mellish, Y. Qu, N. Scarsdale, N. Farrell. Nucleic Acids Res. 25, 1265 (1997). (http://dx.doi.org/10.1093/nar/25.6.1265)
17. R. Zaludova, A. Zakovska, J. Kasparkova, Z. Balcarova, V. Kleinwächter, O. Vrana, N. Farrell, V. Brabec. Eur. J. Biochem. 246, 508 (1997). (http://dx.doi.org/10.1111/j.1432-1033.1997.00508.x)
18. J. Kasparkova, O. Novakova, O. Vrana, N. Farrell, V. Brabec. Biochemistry 38, 10997 (1999). (http://dx.doi.org/10.1021/bi990245s)
19. J. Kasparkova, N. Farrell, V. Brabec. J. Biol. Chem. 275, 15789 (2000). (http://dx.doi.org/10.1074/jbc.M000777200)
20. V. Brabec, M. Leng. Proc. Natl. Acad. Sci. USA 90, 5345 (1993). (http://dx.doi.org/10.1073/pnas.90.11.5345)
21. A. M. J. Fichtinger-Schepman, J. L. Van der Veer, J. H. J. Den Hartog, P. H. M. Lohman, J. Reedijk. Biochemistry 24, 707 (1985). (http://dx.doi.org/10.1021/bi00324a025)
22. M. E. Oehlsen, Y. Qu, N. Farrell. Inorg. Chem. 42, 5498 (2003). (http://dx.doi.org/10.1021/ic030045b)
23. N. Summa, J. Maigut, R. Puchta, R. van Eldik. Inorg. Chem. 46, 2094 (2007). (http://dx.doi.org/10.1021/ic061990d)
24. V. Brabec, J. Kasparkova. Drug Resist. Updates 8, 131 (2005). (http://dx.doi.org/10.1016/j.drup.2005.04.006)
25. Y. Jung, S. J. Lippard. Chem. Rev. 107, 1387 (2007). (http://dx.doi.org/10.1021/cr068207j)
26. Z. H. Siddik. Oncogene 22, 7265 (2003). (http://dx.doi.org/10.1038/sj.onc.1206933)
27. D. P. Bancroft, C. A. Lepre, S. J. Lippard. J. Am. Chem. Soc. 112, 6860 (1990). (http://dx.doi.org/10.1021/ja00175a020)
28. J. Kasparkova, J. Zehnulova, N. Farrell, V. Brabec. J. Biol. Chem. 277, 48076 (2002). (http://dx.doi.org/10.1074/jbc.M208016200)
29. L. Zerzankova, H. Kostrhunova, M. Vojtiskova, O. Novakova, T. Suchankova, M. Lin, Z. Guo, J. Kasparkova, V. Brabec. Biochem. Pharmacol. 80, 344 (2010). (http://dx.doi.org/10.1016/j.bcp.2010.04.013)
30. L. Zerzankova, T. Suchankova, O. Vrana, N. P. Farrell, V. Brabec, J. Kasparkova. Biochem. Pharmacol. 79, 112 (2010). (http://dx.doi.org/10.1016/j.bcp.2009.08.009)
31. V. Brabec, V. Kleinwächter, J. L. Butour, N. P. Johnson. Biophys. Chem. 35, 129 (1990). (http://dx.doi.org/10.1016/0301-4622(90)80003-P)
32. R. Zaludova, V. Kleinwächter, V. Brabec. Biophys. Chem. 60, 135 (1996). (http://dx.doi.org/10.1016/0301-4622(96)00010-5)
33. C. Schildkraut, S. Lifson. Biopolymers 3, 195 (1965). (http://dx.doi.org/10.1002/bip.360030207)
34. E. L. M. Lempers, K. Inagaki, J. Reedijk. Inorg. Chim. Acta 152, 201 (1988). (http://dx.doi.org/10.1016/S0020-1693(00)84952-X)
35. E. L. M. Lempers, J. Reedijk. Inorg. Chem. 29, 217 (1990). (http://dx.doi.org/10.1021/ic00327a014)
36. J. Reedijk. Chem. Rev. 99, 2499 (1999). (http://dx.doi.org/10.1021/cr980422f)
37. X. Wang, Z. Guo. Anti-Cancer Agents Med. Chem. 7, 19 (2007). (http://dx.doi.org/10.2174/187152007779314062)
38. J. C. Dabrowiak, J. Goodisman, A. K. Souid. Drug Metab. Dispos. 30, 1378 (2002). (http://dx.doi.org/10.1124/dmd.30.12.1378)
39. S. Akiyama, Z. S. Chen, T. Sumizawa, T. Furukawa. Anti-Cancer Drug Des. 14, 143 (1999).
40. G. Chen, K. J. Hutter, W. J. Zeller. Cell Biol. Toxicol. 11, 273 (1995). (http://dx.doi.org/10.1007/BF00757625)
41. L. R. Kelland. Drugs 59, 1 (2000). (http://dx.doi.org/10.2165/00003495-200059004-00001)
42. D. Hagrman, J. Goodisman, J. C. Dabrowiak, A. K. Souid. Drug Metab. Disp. 31, 916 (2003). (http://dx.doi.org/10.1124/dmd.31.7.916)
43. T. G. Appleton, J. W. Connor, J. R. Hall, P. D. Prenzler. Inorg. Chem. 28, 2030 (1989). (http://dx.doi.org/10.1021/ic00310a007)
44. S. J. Berners-Price, P. W. Kuchel. J. Inorg. Biochem. 38, 305 (1990). (http://dx.doi.org/10.1016/0162-0134(90)80005-I)
45. Y. Zhao, W. He, P. Shi, J. Zhu, L. Qiu, L. Linb, Z. Guo. Dalton Trans. 2617 (2006). (http://dx.doi.org/10.1039/b601739h)
46. T. Li, H. Lin, T. Li, W. He, Y. Li, Y. Zhang, Y. Zhu, Z. Guo. Inorg. Chim. Acta 362, 967 (2009). (http://dx.doi.org/10.1016/j.ica.2008.01.003)
47. X. Y. Wang, Z. J. Guo. Dalton Trans. 1521 (2008). (http://dx.doi.org/10.1039/b715903j)

Pure and Applied Chemistry

Navigation

PAC Archives

RSS Feeds

Highlights

Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-Pt^II complexes containing long alkane linkers

References

Pure and Applied Chemistry

Navigation

Search PAC

PAC Archives

RSS Feeds

Highlights

Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-PtII complexes containing long alkane linkers

References

Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-Pt^II complexes containing long alkane linkers